Author Archives: admin


Stem Cell Clinic > Articles by: admin

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue…

By Stem Cell Medicine

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2020. The Company's six-month progress includes the development of several strategic initiatives, including growth-oriented opportunities in pain management and COVID-19 related therapeutics.

"Despite the COVID-19 pandemic business disruptions and the near-term delays to completing and commencing our clinical programs in Israel and the U.S., respectively, we acted swiftly over the past few months to leverage our sought-after technology to create several long-term business initiatives to enhance our value," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to pursuing a potential merger with a global leader in the high growth medical-grade cannabis market, which is being delayed due to COVID-19, we have either initiated or are contemplating other business development activities that will greatly benefit from our innovation, technology and know-how. I believe each of these opportunities represents meaningful catalysts for Cellect in multi-billion-dollar markets, subject to resolution of the COVID-19 pandemic and return to normal course of business."

Notwithstanding the continued delays due to COVID-19, the Company remains focused on the following operational and clinical objectives:

The Company's cash and cash equivalents totaled $7 million as of June 30, 2020, which includes the approximately $1.5 million (gross before expenses)resulting from several investors exercising certain warrants that were issued in February 2019.

SecondQuarter 2020 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2020 (U.S. $1 = NIS 3.466).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2020

2020

2019

2020

2019

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

837

2,901

7,086

1,364

3,564

General and administrative expenses

1,356

4,703

5,064

2,116

2,709

Operating loss

2,193

7,604

12,150

3,480

6,273

Financial expenses (income) due to warrants exercisable into shares

1,098

3,807

(7,111)

4,697

(5,919)

Other financial expenses (income), net

(15)

(55)

880

627

462

Total comprehensive loss

3,276

11,356

5,919

8,804

816

Loss per share:

Basic and diluted loss per share

0.010

0.034

0.029

0.024

0.004

Weighted average number of shares outstanding used to compute basic and diluted loss per share

338,182,275

338,182,275

200,942,871

365,428,101

224,087,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

Convenience

translation

June 30,

June 30,

December 31,

2020

2020

2019

Unaudited

Unaudited

Go here to read the rest:
Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue...

California Propositions on the 2020 Ballot – Fullerton Observer

By Stem Cell Medicine

Local News

In addition to voting for candidates, California voters will be asked to vote on several ballot measures this November. Heres a breakdown of each Proposition on the ballot.

Prop. 14: Stem Cell Research Funding

Would issue $5.5 billion in bonds for the California Institute for Regenerative Medicine (CIRM), which was created to fund stem cell research.

Support has raised $6.58 million, with $4.63 million from Robert N. Klein II, a real estate investor and stem-cell research advocate.

There were no committees registered to oppose the ballot initiative.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 15: Property Tax Increase on Commercial and Industrial Properties for Education and Local Government Funding

Would allow commercial and industrial properties (with some exceptions) to be taxed based on their market value, as opposed to their assessed value. Residential properties would not be affected. The State fiscal analyst estimated that the ballot initiative would generate between $8 billion and $12.5 billion in revenue per year. Revenue would be distributed mostly to local governments, school districts, and community colleges.

Support has raised $21 million, including $6 million from the California Teachers Association Issues PAC.

Opposition has raised $5.5 million, including $266,490 from the California Business Roundtable Issues PAC.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 16: Ending the Ban on Affirmative Action

Would remove the ban on affirmative action involving race-based or sex-based preferences from the California Constitution by repealing Proposition 209 (1996). State and local governments, public universities, and other public entities wouldwithin the limits of federal lawbe allowed to develop and use affirmative action programs that grant preferences based on race, sex, color, ethnicity, and national origin in public employment, public education, and public contracting.

Support has raised $3.14 million. M. Quinn Delaney is the largest donor, contributing $1,500,000.

Opposition has raised $105,678, including $50,000 from Students for Fair Admissions, Inc.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 17: Restoring the Right to Vote to People on Parole

Would allow people on parole for felony convictions to vote in California. Currently, the California Constitution disqualifies people with felonies from voting until their imprisonment and parole are completed.

Campaign finance data has not been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 18: Letting (some) 17-year-olds Vote

Would allow 17-year-olds who will be 18 at the time of the next general election to vote in primary elections and special elections.

Campaign finance data has not been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 19: Property Tax Breaks

Would allow homeowners who are over 55, disabled, or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a State fire response fund.

Support has raised $19.15 million with $15.70 million from The California Association of Realtors Issues Mobilization PAC.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 20: Criminal Sentencing, Parole, and DNA Collection Initiative

Would amend several criminal sentencing and supervision laws that were passed between 2011 and 2016.

Would allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole 3 times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Support has raised $1.6 million with $50,000 from San Bernadino County Sheriffs Employees Benefit Association Committee.

Opposition has raised $2.1 million with major funding from the Schusterman Foundation, the Heising-Simons Action Fund, and Patty Quillin.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 21: Local Rent Control Initiative

Would allow cities to introduce new rent control laws, or expand existing ones.

Support has raised $16.68 million, with 99.8% from the AIDS Healthcare Foundation.

Opposition has raised $16.25 million, including $4.70 million from Essex Property Trust, $117,000 from California Rental Housing Association, and other property owner groups.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 22: Self-employment for ride-hail and other app-drivers

Would consider app-based drivers to be independent contractors and not employees or agents. Therefore, the ballot measure would override Assembly Bill 5 (AB 5), signed in September 2019, on the question of whether app-based drivers are employees or independent contractors.

Support has raised $111 million, including $30 million from Lyft, $30 million from Uber, and $30 million from DoorDash.

Opposition has raised $866,591, with the Transport Workers Union of America providing $500,000.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 23: Dialysis Clinic Requirements

Would require chronic dialysis clinics to have a minimum of one licensed physician present at the clinic and to report data on dialysis-related infections to the State and federal health officials.

The ballot measure would also state that a chronic dialysis clinic cannot discriminate with respect to offering or providing care nor refuse to offer or to provide care, on the basis of who is responsible for paying for a patients treatment.

Support has raised $6 million from a healthcare workers union.

Opposition has raised $2 million, with $1 million from DaVita, Inc. and $1 million from Fresenius Medical Care (dialysis clinics).

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 24: Consumer Privacy Protections

Would strengthen Californias consumer privacy law and establish a California Privacy Protection Agency.

Support has raised $4.76 million with most funding from developer Alastair Mactaggart.

No opposition funding has been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 25: Replace Cash Bail with Risk Assessments

Would end the States cash bail system and give judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Support has raised $1.36 million. Action Now Initiative was the largest donor, contributing $500,000.

Opposition has raised $4.24 million, including $921,633. from Triton Management Services, LLC and the bail bond industry.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Visit the California Secretary of State ballot measures page HERE.

Orange County voters will have three options for returning their ballots.

Protect local journalism please subscribe to the print edition of the Fullerton Observer. Our online edition is free, but we depend on print subscriptions from readers. Annual subscription is only $35/year.It only takes a minute Click Here To Subscribe. Thank you for your support for the Fullerton Observer. Click here to view a copy of the print edition.

Continued here:
California Propositions on the 2020 Ballot - Fullerton Observer

Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes – delawarebusinessnow.com

By Stem Cell Medicine

ViaCyte, Inc. and Newark-based W. L. Gore & Associates, Inc. announced the two companies have signed an agreement covering the next phase of their collaboration focused on the development of ViaCytes Encaptra Cell Delivery System that uses Gore material technologies.

The technology is designed to produce insulin for patients with Type I diabetes, formerly known as juvenile diabetes.

The Encaptra System could be a transformative therapy for patients with type 1 diabetes, the companies noted.

Tapping into Gores world-class materials science and medical device expertise, new membrane technology was developed that appears to allow successful engraftment and beta cell proliferation while minimizing the host foreign body response, said Paul Laikind, CEO of ViaCyte. This agreement is an important next step on our path towards a commercial product as well as a template for future agreements for additional work ViaCyte and Gore may do together on cell delivery technology.

Our collaboration with ViaCyte has been very productive in enabling the clinical advancement of the PEC-Encap product candidate with proprietary Gore materials technology, said Erin Hutchinson, business leader, Gore PharmBIO Cell Encapsulation Products. We are delighted to further strengthen our collaboration on the path to the delivery of a potentially functional curative product for those currently suffering with type 1 diabetes and help pioneer the new field of cell replacement therapy.

ViaCyte is the only company with stem cell-derived islet replacement candidates undergoing clinical testing and the only group to show that the implanted cells are capable of producing insulin in people with type 1 diabetes.

The Companys promising candidates have the potential to deliver a functional cure for people with type 1 diabetes and could be an advancement for people with insulin-requiring type 2 diabetes.

Under the terms of the agreement, Gore will manufacture and supply a proprietary membrane and the device component for use with ViaCytes PEC-Encap product candidate.

The novel Gore membrane has been evaluated in preclinical studies. Gore will continue to collaborate with ViaCyte to optimize the device design and implant techniques in support of human clinical trials.

Early human clinical trials of PEC-Encap with the new membrane are underway and preliminary histological results are encouraging. Should the membrane prove successful in the ongoing trial, Gore will assume the responsibility for manufacturing the Encaptra System incorporating the novel membrane technology for late stage clinical development and commercial use.

ViaCyte has shown that once implanted and successfully engrafted PEC-01 cells mature into beta cells that secrete insulin in a regulated manner to control blood glucose levels. The Encaptra System serves to protect the PEC-01 cells from the host immune system thus eliminating the need for immune suppression drugs commonly used with other transplants.

A critical enabling component of the Encaptra System that contains and protects the cells is a specifically designed semi-permeable membrane that encapsulates the cells but allows for diffusion of oxygen and nutrients into the device and insulin and other hormones out of the device and into the circulation.

The Encaptra System membrane is composed of an expanded PTFE composite, similar to materials that are used in Gores implantable medical products..

Gore and ViaCyte began a collaboration in 2017.

ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. ViaCyte is headquartered in San Diego.

Continue reading here:
Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes - delawarebusinessnow.com

FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast COVID-19 Cell Therapy Reduces…

By Stem Cell Medicine

HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) FibroGenesis, a clinical stage company developing fibroblast based therapeutic solutions for unmet medical needs, announced today new data supporting utilization of its PneumoBlast product in treatment of COVID-19. Laboratory experiments comprised of admixing PneumoBlast with activated monocyte or endothelial cells demonstrated significant inhibition of tissue factor expression. Tissue factor is the key molecule inducing blood clotting in COVID-19 patients. Monocytes are cells which normally protect the body against pathogens. In the case of COVID-19, monocytes enter the lungs and cause coagulation. Endothelial cells are cells which make up the inside of the blood vessel and regulate substance flow between the bloodstream and surrounding tissues.

It was observed that treatment of activated monocytes with PneumoBlast resulted in a 77% reduction of tissue factor expression as compared to untreated monocytes (p,lt; 0.001). Mixture of mesenchymal stem cells with activated monocytes resulted in a 13% inhibition of tissue factor expression (p= 0.01). Furthermore, in activated endothelial cells, PneumoBlast decreased expression of tissue factor by 80% (p,lt; 0.001), whereas mesenchymal stem cells resulted in a 30% (p= 0.01) reduction.

It is believed that a significant cause of morbidity and mortality in COVID-19 occurs because of unrestrained blood clotting. Studies have shown the high propensity for clotting in COVID-19 patients is associated with inflammation. The Company previously demonstrated PneumoBlast reduces proteins necessary for inflammation, such as TNF-alpha. The current study shows PneumoBlast can also work downstream of inflammation and directly suppress the clotting cascade.

This data is truly stunning, said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. Currently one of the major obstacles to successful treatment of COVID-19 is the unusually high level of unregulated coagulation, which in many cases is not resolved by standard anticoagulants. The ability of PneumoBlast cells to reduce blood clotting potential in both monocytic and endothelial cells speaks volumes about the multifactorial mechanisms by which we believe our product will work on COVID-19.

We are thankful for our team of clinical collaborators and scientists who are exploring and identifying novel mechanisms by which PneumoBlast appears to be effective against COVID-19, commented Pete OHeeron, President and CEO of FibroGenesis. We are the first cell therapy company to address the issue of coagulation in COVID-19. We see this, as another indication of the superiority of fibroblasts compared to stem cells.

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinsons, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Read this article:
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast COVID-19 Cell Therapy Reduces...

Global Canine Stem Cell Therapy Market 2027 Register a Xx% CAGR In Terms Of Revenue: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana…

By Stem Cell Clinics

Canine Stem Cell Therapy Market

DataIntelo, 12-08-2020: The research report on the Canine Stem Cell Therapy Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=82309

The Major Manufacturers Covered in this Report: VETSTEM BIOPHARMA Cell Therapy Sciences Regeneus Aratana Therapeutics Medivet Biologics Okyanos Vetbiologics VetMatrix Magellan Stem Cells ANIMAL CELL THERAPIES Stemcellvet

The Research Study Focuses on:

By Types: Allogeneic Stem Cells Autologous Stem cells

By Applications: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=82309

The Canine Stem Cell Therapy Market Report Consists of the Following Points:

Make an Inquiry of the Canine Stem Cell Therapy Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=82309

In conclusion, the Canine Stem Cell Therapy Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

See the article here:
Global Canine Stem Cell Therapy Market 2027 Register a Xx% CAGR In Terms Of Revenue: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana...

Joliet toddler with cancer missed 2nd birthday at home due to Chicago riots – The Herald-News

By Stem Cell Clinics

Owen Buell of Joliet has gone through a lot in his short toddler life.

In February, Owen was diagnosed with a neuroblastoma, a type of cancer most commonly found in children age 5 or younger.

Hes had chemotherapy, and he had the first of two stem cell transplants on July 8.

And even when Owen went to a nearby Ronald McDonald House, he returned to the hospital for three days due to an infection his central line, said his grandmother, Jackie Moore of Florida.

Owen has had a feeding tube, numerous ports, bone marrow tests, stem cell extractions, major abdominal surgery, according to The Help for Baby Owen Buell and his Family Facebook page, which Moore moderates.

So you can imagine how excited his family was to celebrate his second birthday Monday. Moore even shipped a 3-foot-tall stuffed llama to Owens home to surprise him because Owen loves llamas.

Except Owen didnt get to see the llama.

Or any of his other birthday gifts.

He wasnt there.

Owen and his parents, Brian Buell and Valerie Mitchell, were at a Ronald McDonald House in Chicago. The Ann & Robert H. Lurie Childrens Hospital of Chicago was supposed to discharge him on Monday, but that didnt happen because of the riots, Moore said.

The hospital website said some clinics might be canceled due to unrest in the city.

Moore said shes upset, not just for Owen and his parents, but also for the other families at Ronald McDonald House with children who are also fighting for their lives.

Can you imagine those kids being inside and listening to this? Moore said. They can still look out the windows and hear the sirens and hear the gunshots. Its terrifying.

Moores also worried about the food situation for the families at the Ronald McDonald House.

Meals are freshly made meals provided by caring volunteers, according to the Ronald McDonald House Charities of Chicagoland & NW Indiana website.

Moores afraid volunteers wont be able to get near the Ronald McDonald House to bring nourishing meals or restock supplies.

There might be Twinkies and Zingers and fruit chews, Moore said. But its not a meal.

When Owen is finally discharged, he will come home with a shopping bag full of medical supplies, Moore said.

In a few weeks, Owen will resume is cancer treatments in preparation for a second stem cell transplant.

The goal of the transplant is to make his bones more receptive to the chemo and possibly have him go into remission, according to the Help for Baby Owen Buell and his Family Facebook page.

In the meantime, Owens brothers, Elliott, age 7, and Bentley, age 4, decorated the house for the occasion, Moore said.

Owens gifts are waiting for him to unwrap them.

I told my daughter, Put the cake in the refrigerator, Moore said. At 2 years old, he doesnt know its his birthday. Hell be just as happy tomorrow if he can go home.

She paused.

And I hope he likes the llama Grandma got him, she said.

Donate to Owen through GoFundMe at bit.ly/2S7sPN7.

See original here:
Joliet toddler with cancer missed 2nd birthday at home due to Chicago riots - The Herald-News

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. – Good Night, Good…

By Stem Cell Clinics

Global Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Cell Therapy Technologies Market: Overview

Cell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: Drivers and Restraints

The growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market. in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation Analysis

On the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional Analysis

North America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & Software Global Cell Therapy Technologies Market, by Cell Type

Human Cells Animal Cells Global Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality Control Global Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research Institutes Global Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South America Key players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Go here to read the rest:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) by Product, Technique, End Users and Region. - Good Night, Good...

RenovaCare Receives FDA Conditional IDE Approval of CellMist System and SkinGun Device, Enabling Clinical Study for Safety and Feasibility – BioSpace

By Stell Cell Research

ROSELAND, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Renovacare, Inc. (Symbol: RCAR; http://www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the US Food and Drug Administration (FDA)conditionally approved the Companys Investigational Device Exemption (IDE) application to conduct a clinical trial to evaluate the safety and feasibility of autologous stem cells rendered by its CellMist System from donor skin and applied topically with the SkinGun spray device for treatment of burn wounds.

"The FDA conditional approval marks a significant milestone for RenovaCare and our technology for spraying an ultra-gentle mist of a patients own skin cells for the healing of burns and wounds. We are working to complete the FDA's technical requirements so that we may move forward with the next phase of development," stated Alan L. Rubino, the Company's President and Chief Executive Officer.

The clinical trial protocol, conditionally approved on August 5, 2020 by the FDA is an open-label single-arm clinical study that will enroll 14 human burn subjects with partial-thickness second- or- third degree thermal burn wounds. The Company expects to conduct the clinical study at multiple U.S. burn centers.

"This achievement marks the culmination of our innovative stem cell and spray technologies coupled to applied research and development resulting in a formal clinical evaluation of skin stem cells as a therapeutic to facilitate burn wound healing," stated RenovaCare Chief Scientific Officer, Dr. Robin A. Robinson. "I am proud of our RenovaCare Team and their dedication to our mission and commitment to provide effective and expedited patient healing and look forward to commencing this study as quickly as possible."

About RenovaCare RenovaCare, Inc. is developing new generation autologous stem cell therapies for the regeneration of human organs and tissues. The Company's initial product under development targets the bodys largest organ, the skin. The Companys flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates rapid healing of wounds or other afflicted tissues when applied topically as a gentle cell mist using the patented RenovaCare SkinGun. The Companys SkinGun is used to spray a liquid suspension of a patients stem cells the CellMist Solution on to wounds.

RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.

Development for next-generation biomedical technologies and devices for addressing unmet medical needs and commercialization is taking place at the RenovaCare R&D Innovation Center, located at StemCell Systems in Berlin, Germany. The Innovation Center houses dedicated RenovaCare cell biology laboratories; additional engineering, fabrication, prototyping and performance testing facilities; and product design studios for medical devices and biomedical products. Experienced contract bioengineers, cell biologists, and support staff work under the direction of a team of MD-PhDs who are experts in regenerative medicine, new product development, and clinical translation.

RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Companys planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.

For additional information, please call Amit Singh at: 1-888-398-0202 or visit:https://renovacareinc.com

To receive future press releases via email, please visit: https://renovacareinc.com/investors/register/

Follow us on LinkedIn:https://www.linkedin.com/company/renovacare-inc-/

Follow us on Twitter:https://twitter.com/RenovaCareInc

Follow us on Facebook:https://www.facebook.com/renovacarercar

Social Media Disclaimer Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first.

We encourage investors, the media, and others interested in the company to review the information we post on the companys website and the social media channels listed below:

* This list may be updated from time to time.

Legal Notice Regarding Forward-Looking Statements No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the Company) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words may, will, should, could, expect, anticipate, estimate, believe, intend, or project or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Companys product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Companys technologies, technical problems with the Companys research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Companys operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Companys ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Companys most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission athttp://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Originally posted here:
RenovaCare Receives FDA Conditional IDE Approval of CellMist System and SkinGun Device, Enabling Clinical Study for Safety and Feasibility - BioSpace

Trumps Unprecedented Attacks on Our Public-Health System – The New Yorker

By Stell Cell Research

How worried should we be that the President of the United States recently described as very impressive a woman who claims that doctors make medicine using DNA from aliens? Or that he shows no sign of recognizing the magnitude of the COVID-19 pandemic? Its simply not possible to worry too much.

I thought her voice was an important voice, Donald Trump said, after a reporter asked him why he would retweet the claims of Stella Immanuel, a Houston pediatrician with a long history of bizarre statements about medicine and human sexuality. Immanuel also shares Trumps unfounded enthusiasm for hydroxychloroquine. The drug has been repeatedly discredited as a treatment for this disease. She insists that it is a cure. Its tempting to write off this episode purely as evidence of Trumps disrespect for science. But the problem it represents is much bigger; it is the clearest sign yet that political interests and personal whims have eclipsed the rigor of some of our most important scientific institutions.

Read The New Yorkers complete news coverage and analysis of the coronavirus pandemic.

Twenty years ago, reporting from South Africa, I saw firsthand what happens when a national leader forces his people to subsist on lies and magic. From 2000 to 2005, according to a definitive study by researchers at the Harvard School of Public Health, Thabo Mbeki, then the President of South Africa, let as many as three hundred and thirty thousand of his fellow-citizens die and thirty-five thousand babies be born with H.I.V., by refusing to permit the countrys health service to treat AIDS with antiretroviral drugs. Mbeki and his health minister, Manto Tshabalala-Msimang, insisted that antiviral medicine was the product of a plot by Western pharmaceutical companies to kill Africans. The Harvard study concluded that the drugs were withheld largely because of Mbekis well-known refusal to initially accept that AIDS is caused by a virus, H.I.V.

No single national leader would have been able to prevent the coronavirus pandemic. But Trumps denialism and hostility toward public-health officials has greatly increased Americas share of suffering and death. On Fox & Friends, on Wednesday, he said that the virus is spreading in a relatively small portion of the country, and that children are virtually immune; both statements are false. And, as he has done many times before, he declared at a briefing that the pandemic would just go away.

Trump has had one consistent response to the pandemic: he attacks leading experts when they attempt to tell the truth. Last week, when Deborah Birx, the cordinator of the White House coronavirus task force, characterized the epidemic as extraordinarily widespread, Trump tweeted that she was pathetic. Earlier this year, when Anthony Fauci, the nations leading infectious-disease expert, was asked at a briefing to discuss his view on hydroxychloroquine, Trump prevented him from answering. The Presidents refusal either to lead or to recognize the leadership of others has made it impossible to develop a national plan to combat this virus.

Without such a plan, the nation has been subjected to a giant game of viral roulette. With no coherent system of rapid tests, contact tracing is all but useless. Since we have neither a vaccine nor any general therapy, tests and tracing offer the only near-term hope of controlling the pandemic. States have largely been left to fend for themselves. Last week, seven governors, Republicans and Democrats, formed their own testing coalition.

On Wednesday, Fauci was asked if the United States had the worlds worst COVID-19 outbreak. It is quantitatively, if you look at it, he said. I mean, the numbers dont lie. Trump is asked similar questions nearly every day. And, although the numbers may not lie, the President does. As he put it in a recent tweet, You will never hear this on the Fake News concerning the China Virus, but by comparison to most other countries, who are suffering greatly, we are doing very well. No amount of statistical massaging could make that statement true.

This war on reality has deeply wounded Americas public-health system. In March, under relentless pressure from Trump and his trade adviser, Peter Navarro (who has no medical training), the Food and Drug Administration issued an emergency-use authorization (E.U.A.) for hydroxychloroquine. That allowed doctors to administer the drug to patients who were severely ill, but it was not an approval of the drug for general use. As Janet Woodcock, who runs the F.D.A.s Center for Drug Evaluation and Research, put it in an interview with Stat, We simply said its possible from the in vitro data this may have a beneficial effect and the benefits may outweigh the risks. Few people understood that distinction, and, goaded on by the President, few listened to those who urged caution.

Trump announced on national television that hydroxychloroquine could be a game changer. It wasnt. Former F.D.A. officials were astonished by the rushed action. I understand the desire to find hope, but we need more evidence than is currently available before we encourage widespread use, Margaret A. Hamburg said at the time. She served as the F.D.A. commissioner for six years under Barack Obama.

In June, when the drugs ineffectiveness had become apparent, the F.D.A. revoked the E.U.A. It was a remarkable retreat. While it is reassuring that the agency finally made a decision based on data, the drug should not have been released for this use in the first place. But, when politics takes precedence, facts no longer matter. Rick A. Bright, one of the nations experts on pandemic preparedness and the chief of BARDA (the Biomedical Advanced Research and Development Authority), had objected to the use of the drug and tried to stop it. He was fired. As the Times reported on Monday, Stephen Hahn, the current F.D.A. commissioner, is not allowed to speak to the press unless Michael Caputo, an assistant secretary of the Department of Health and Human Services, or another official, is also on the line. Caputo has long been associated with Trump, once serving as his driver.

We have recently witnessed an even more pernicious example of an American scientific colossus bowing to Trumps ignorance. In May, the Centers for Disease Control and Prevention issued stringent guidelines to determine when and if schools should reopen this fall. Trump has insisted, against all scientific advice, that all schools should open. He tweeted, I disagree with the @CDCgov on their very tough & expensive guidelines for opening schools. While they want them open, they are asking schools to do very impractical things. I will be meeting with them!!!

Robert Redfield, the director of the C.D.C., immediately issued an update to the guidelines, announcing that it is critically important for our public health to open schools this fall. The reversal was stunning; past C.D.C. directors were not immune to politics, and they understood that a President might overrule them. But there has always been an understanding at the agency that all public-health decisions made there would have to be governed by data.

No agency or scientist is infallible. Early in the pandemic, the C.D.C. failed to introduce accurate test kits; many of the kits it distributed were contaminated and useless. The agency used highly sensitive tests based on PCR technology, which is a kind of molecular copying machine that makes millions (or billions) of copies of a DNA sample. That makes it much easier for clinicians to detect any specific sequence of DNA, including those in the coronavirus. The technology has been used routinely for more than three decades, but it is sensitive to small errors, and there were several in the C.D.C. kits. The misstep delayed accurate data collection throughout the United States at one of the most critical moments in the pandemic.

Originally posted here:
Trumps Unprecedented Attacks on Our Public-Health System - The New Yorker

Stem Cell Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2027 – Owned

By Stell Cell Research

Allosource

Stem Cell Therapy Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

Stem Cell Therapy Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Stem Cell Therapy Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Asia, and South America. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

North America(United States, Canada, and Mexico) Europe(Germany, France, UK, Russia, and Italy) Asia-Pacific(China, Japan, Korea, India, and Southeast Asia) South America(Brazil, Argentina, Colombia, etc.) The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Why purchase this report

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Go here to see the original:
Stem Cell Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2027 - Owned

→←